ST南卫(603880) - 2020 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 1.41% to CNY 9,432,898.99 year-on-year[6] - Operating revenue decreased slightly by 0.08% to CNY 100,435,111.68 compared to the same period last year[6] - Basic earnings per share rose by 1.42% to CNY 0.05582[6] - Net profit for Q1 2020 was CNY 9,289,562.19, compared to CNY 9,414,948.60 in Q1 2019, reflecting a decrease of approximately 1.33%[27] - The company's revenue for Q1 2020 was ¥97,334,274.40, a decrease of 1.64% compared to ¥98,951,847.92 in Q1 2019[29] - Operating profit for Q1 2020 increased to ¥11,019,443.49, up 11.25% from ¥9,906,144.94 in Q1 2019[30] - Net profit for Q1 2020 was ¥9,814,291.57, representing a 16.63% increase from ¥8,414,347.10 in Q1 2019[30] Cash Flow - Net cash flow from operating activities showed a significant decline of 153.85%, amounting to -CNY 6,076,249.05[6] - Net cash flow from operating activities was negative at CNY -6,076,249.05, mainly due to increased material purchases[14] - Net cash flow from investing activities was negative at CNY -35,770,162.50, primarily due to project payments by subsidiaries[14] - The company reported a net cash outflow from operating activities of ¥6,076,249.05 in Q1 2020, compared to a net inflow of ¥11,284,653.07 in Q1 2019[32] - The company experienced a decrease in total cash flow from investing activities, with a net outflow of ¥35,770,162.50 in Q1 2020 compared to a net inflow of ¥34,238,330.04 in Q1 2019[32] - Cash and cash equivalents decreased by $3,167,225.94, while the previous period saw an increase of $50,354,322.32[36] - The ending balance of cash and cash equivalents was $113,883,347.89, down from $194,331,150.06 in the previous period[36] Assets and Liabilities - Total assets increased by 3.27% to CNY 898,068,339.05 compared to the end of the previous year[6] - Total liabilities increased to CNY 320,811,229.86 from CNY 302,078,657.35[20] - The company's total assets as of March 31, 2020, were CNY 870,207,701.31, an increase from CNY 818,265,479.84 at the end of 2019, representing a growth of about 6.35%[23] - Current assets totaled CNY 475,004,441.73 as of March 31, 2020, up from CNY 429,509,695.56 at the end of 2019, indicating an increase of approximately 10.59%[22] - The total liabilities as of March 31, 2020, were CNY 289,471,093.48, compared to CNY 247,343,163.58 at the end of 2019, reflecting an increase of approximately 17.0%[23] - The company's equity increased to CNY 580,736,607.83 from CNY 570,922,316.26, representing a growth of about 1.4%[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 20,000[11] - The largest shareholder, Li Ping, holds 44.48% of the shares, with 75,162,750 shares pledged[12] Investment and Development - Non-recurring gains and losses totaled CNY 693,858.21, including CNY 666,350.52 from the disposal of non-current assets[9] - Long-term equity investments surged by 3508.13% to CNY 54,546,291.75, attributed to the completion of an investment in Jiangsu Pharmaceutical Company[14] - Investment income rose by 403.62% to CNY 1,458,660.29, primarily from external investment returns[14] - The company has not reported any significant new product developments or market expansion strategies in this quarter[13] - The company did not apply new revenue and lease standards for the current year[36] - The company did not have an audit report applicable for the current period[36] Expenses - The company reported a decrease in research and development expenses to CNY 3,709,559.07 from CNY 4,650,959.32, a reduction of about 20.2%[27] - Research and development expenses decreased to ¥3,709,559.07 in Q1 2020 from ¥4,650,959.32 in Q1 2019, a reduction of 20.2%[29]